US equities |
INTC $119.13 ▼-0.17% MU $1,074.89 ▲+0.00% NVDA $233.95 ▲+0.00% SNDK $1,719.99 ▲+0.00% SPCX $158.96 ▲+0.00% AMD $633.91 ▲+0.00% SDEV $7.48 ▲+0.00% WDC $415.29 ▲+0.00%
FinancialContent

Fractyl Health, Inc. - Common Stock (NQ:GUTS)

0.4066 UNCHANGED
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Fractyl Health, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Thursday's session: gap up and gap down stocks ↗
Via Chartmill
News headline image
Why Did GUTS Stock Plummet Today Despite Positive Gut Therapy Midterm Study? ↗
Six-month data from 40 participants suggest that Revita helps limit weight regain after GLP-1 discontinuation. 
Via Stocktwits
These stocks that are showing activity before the opening bell on Thursday. ↗
Via Chartmill
News headline image
Fractyl Health Announces Compelling 6-Month Randomized REMAIN-1 Midpoint Data Showing Durable Weight Maintenance with Revita® After GLP-1 Discontinuation
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For November 12, 2025 ↗
 
Via Benzinga
GUTS Stock Rallied About 28% Today – Here’s Why ↗
Via Stocktwits
News headline image
Fractyl Health Appoints Lara Smith Weber as Chief Financial Officer to Support Commercial-Stage Preparedness
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health Enters a Catalyst-Rich 2026 Positioned to Define the Post-GLP-1 Weight Maintenance Therapeutic Category
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health Announces Call of Tranche A Warrants Tied to August 2025 Public Offering Following Achievement of Clinical and Trading Milestones
Holders will have until December 30, 2025 to exercise Tranche A Warrants at $1.05 per share, enabling up to $17.9 million in potential gross proceeds 
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health&#39;s Revita Procedure Helps Patients Keep Weight Off After Stopping GLP-1 Drugs ↗
Fractyl Health (NASDAQ: GUTS) released positive 6-month results from its REVEAL-1 study in obese patients who discontinued GLP-1 therapy. 
Via Benzinga
News headline image
Fractyl Health Reports Positive 6-Month REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita® Procedure
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health to Participate in the 8th Annual Evercore Healthcare Conference
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl (GUTS) Q3 2025 Earnings Call Transcript ↗
Fractyl (GUTS) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Fractyl Health Reports Third Quarter 2025 Results; Revita® Clinical Momentum Builds Toward 2026 Pivotal Readout and PMA Filing, Cash Runway Extended into Early 2027
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Preview: Fractyl Health's Earnings ↗
 
Via Benzinga
News headline image
Fractyl Health to Report Third Quarter 2025 Financial Results and Provide Business Updates on November 12, 2025
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health Announces Potent Preclinical Results from RJVA-002, a Dual GIP/GLP-1 Gene Therapy Candidate for Obesity
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Unusual volume stocks are being observed in Wednesday's session. ↗
Discover the stocks with unexpected trading volume in today's session on the US markets. 
Via Chartmill
News headline image
MAGA Stocks Undercard: SNYR GUTS MRM MYSE Under $3 To Watch Now….more inside
Via AB Newswire
Topics Economy
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
Gainers Indaptus Therapeutics (NASDAQ: INDP) stock moved upwards by 108.1% to $6.83 during Friday's regular session. The market value of their outstanding shares is at $3.6 million. 
Via Benzinga
News headline image
What's going on in today's pre-market session ↗
Discover the top movers in Friday's pre-market session and stay informed about market dynamics. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
Gainers bioAffinity Technologies (NASDAQ: BIAF) stock increased by 71.8% to $5.86 during Friday's pre-market session. The company's market cap stands at $4.5 million. 
Via Benzinga
News headline image
Fractyl Health Announces Pricing of $60 Million Underwritten Offering of Common Stock
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health Announces Groundbreaking Data from REMAIN-1 Midpoint Cohort Showing Revita® Maintained Weight Loss After GLP-1 Discontinuation
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
This Broadcom Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
 
Via Benzinga
News headline image
Fractyl Health Expands Board of Directors with Appointments of Industry Leaders to Advance Clinical Execution and Strategic Growth
Appointments include Christopher Thompson, M.D. and Ian Sheffield as Independent Directors 
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
This Oddity Tech Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
 
Via Benzinga
News headline image
Fractyl Health Posts 62% Wider Q2 Loss ↗
Via The Motley Fool
News headline image
FRACTYL HEALTH INC (NASDAQ:GUTS) Reports Wider-Than-Expected Q2 2025 Loss Amid Clinical Progress ↗
Fractyl Health reports Q2 2025 net loss of $27.9M, missing EPS estimates. No revenue, but clinical progress in Revita and Rejuva programs. Stock dips amid investor concerns. 
Via Chartmill
News headline image
Fractyl Health Announces Second Quarter 2025 Financial Results and Business Updates
From Fractyl Health, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >